Grifols is a Spanish global pharmaceutical company specialising in the supply of blood plasma products. The company has three primary divisions: Bioscience, Diagnostic and Hospital that together develop and market blood based products including devices, reagents and instruments and deliver to over more than 90 countries worldwide.
Grifols is headquartered in Barcelona, Spain but produces the capacity of its blood plasma products from three different plants which are based in Span and the USA. The plasma derived therapies are used to treat patients with rare, genetic and life threatening diseases. To partner the production of the blood plasma products Grifols has also set up over 140 plasma donor centres around the US which help provide a plentiful supply for patients who need it following surgery or hospital care.
It was in 1940 when Grifols was set up by Dr Jose Grifols, a haematologist working on the study of blood plasma products. Dr Grifols research led to the development of the plasma pheresis technique; a procedure that is widely used today that involves extracting human plasma whilst re-injecting red blood cells back into the patient donor. With this technique Dr Grifols truly established Grifols as a global name and from then the business grew as the Doctor’s two sons also began research for the company. In the 1990’s the company developed a liquid version of IVIG which was seen as a big development for the company, this was closely followed up with a few acquisitions by Grifols that was no doubt funded by the recent developmental successes; In 2002 Grifols acquired US based Seracare and in 2003 Grifols acquired certain assets of Alpha Therapeutics. The acquisitions continued with the major takeover of Talecris Biotherapeutics in 2011 that placed Grifols as the third largest global manufacturer of plasma-dervied products and provided them with a number of additional donor centres.
As with many companies the partnerships conducted by Grifols has allowed it to expand internationally both in terms of its physical coverage but also through its reach to deliver products. The acquisitions noted above are part of a list of partnerships that also include deals with other global pharma companies such as Mylan and Cadence Pharmaceuticals. Hot off the press for 2014 Grifols has announced that it has closed an acquisition deal with Novartis for its blood diagnostic transfusion unit, a partnership that will surely help to cement Grifols title as the leading supplier of plasma-derived blood products.
Grifols has also set up a separate service called Grifols Partnership which is a Contract Manufacturing Service offered by Laboratorios Grifols SA. This works alongside Grifols Engineering to produce sterile solutions, lipid emulsions, medical devices and plastic components. This additional service adds another dimension to the work of the company and allows it to capture further international customers.
Grifols is often present at a large number of partnering events throughout the year. Partnering events are a great place to meet lots of potential partners face to face in a short space of time.
Events with Grifols presence include but are not limited to:
- BIO International Convention and Business Forum
- BioEurope / BioEurope Spring
For a full list of forthcoming partnering events where you could meet with Grifols in person visit Current Partnering’s Event calendar.
Contacting Grifols for partnering
Grifols can be contacted in relation to partnering through a number of channels. Here is a list of the most common channels:
Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.
See Current Partnering’s event calendar for details of forthcoming events.
Direct contact: there are several sources of direct contact with Grifols' business development team
- Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.
- Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch. website
- LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel.
Many of Grifols' business development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit Grifols' Linkedin Page
Opportunity submission form: the least favourable channel but worth using if you do not have access to the other channels mentioned above. This is the form available on the Grifols' Pharmaceutical website for potential partnering opportunities.
Available reports from Current Partnering
Report: Partnering Agreements with Grifols 2005-2013
Available resources for deal coverage for Grifols
Read: more on Grifols company profile, recent partnering, M&A and financing news and articles
Report: Practical Guide to Finding Partners
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk